Progestin intrauterine device and GnRH analogue for uterus-sparing treatment of endometrial precancers and well-differentiated early endometrial carcinoma in young women

Annals of Oncology

Volumn 22, Issue 3, 2011, Pages 643-649

  Minig, L ^a,b   Franchi, D ^a   Boveri, S ^a   Casadio, C ^a   Bocciolone, L ^a   Sideri, M ^a  

^a EUROPEAN INSTITUTE OF ONCOLOGY   (Italy)

^b Hospital Universitario Madrid Norte Sanchinarro   (Spain)

Author keywords

Endometrial atypical hyperplasia; Fertility sparing; GnRH analogue; Levonorgestrel intrauterine device; Well differentiated endometrial carcinoma

Indexed keywords

CARBOPLATIN; DOXORUBICIN; EPIRUBICIN; GESTAGEN; GONADORELIN DERIVATIVE; LEVONORGESTREL; PACLITAXEL;

ABSENCE OF SIDE EFFECTS; ADULT; ARTICLE; CANCER CHEMOTHERAPY; CANCER RECURRENCE; CANCER RELAPSE; CLINICAL ARTICLE; CONTROLLED CLINICAL TRIAL; DRUG EFFICACY; DRUG SAFETY; EARLY CANCER; ENDOMETRIUM; ENDOMETRIUM CARCINOMA; FEMALE; FOLLOW UP; HORMONAL THERAPY; HUMAN; HUMAN TISSUE; INTRAUTERINE CONTRACEPTIVE DEVICE; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROSPECTIVE STUDY; TUMOR DIFFERENTIATION;

EID: 79952024674     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdq463     Document Type: Article

References (31)

1. Gallup DG, Stock RJ. Adenocarcinoma of the endometrium in women 40 years of age or younger. Obstet Gynecol 1984; 64: 417-420.
2. Soliman PT, Oh JC, Schmeler KM et al. Risk factors for young premenopausal women with endometrial cancer. Obstet Gynecol 2005; 105: 575-580.
3. Emons G, Schroder B, Ortmann O et al. High affinity binding and direct antiproliferative effects of luteinizing hormone-releasing hormone analogs in human endometrial cancer cell lines. J Clin Endocrinol Metab 1993; 77: 1458-1464.
4. Kinkel K, Kaji Y, Yu KK et al. Radiologic staging in patients with endometrial cancer: a meta-analysis. Radiology 1999; 212: 711-718.
5. ACOG Committee Opinion # 337. Noncontraceptive uses of levonorgestrel intrauterine device system. Obstet Gynecol 2006; 107: 1479-1482.
6. Toivonen J, Luukkainen T. Progestin-releasing intrauterine devices. Curr Ther Endocrinol Metab 1997; 6: 281-285.
7. Kurman RJ, Norris HJ. Evaluation of criteria for distinguishing atypical endometrial hyperplasia from well-differentiated carcinoma. Cancer 1982; 49: 2547-2559.
8. Mutch D. The new FIGO staging system for cancers of the vulva, cervix, endometrium and sarcomas. Gynecol Oncol 2009; 115: 325-328.
9. Guttinger A, Critchley H. Endometrial effects of intrauterine levonorgestrel. Contraception 2007; 75: S93-S98.
10. Luukkainen T, Lahteenmaki P, Toivonen J. Levonorgestrel-releasing intrauterine device. Ann Med 1990; 22: 85-90.
11. Signorelli M, Caspani G, Bonazzi C et al. Fertility-sparing treatment in young women with endometrial cancer or atypical complex hyperplasia: a prospective single-institution experience of 21 cases. Br J Obstet Gynaecol 2009; 116: 114-118.
12. Chiva de Agustín L, Lapuente Sastre F, Corraliza Galán V et al. Conservative management of patients with early endometrial carcinoma: a systematic review. Clin Transl Oncol 2008; 10: 155-162.
13. Ramirez PT, Frumovitz M, Bodurka DC et al. Hormonal therapy for the management of grade 1 endometrial adenocarcinoma: a literature review. Gynecol Oncol 2004; 95: 133-138.
14. Niwa K, Tagami K, Lian Z et al. Outcome of fertility-preserving treatment in young women with endometrial carcinomas. Br J Obstet Gynaecol 2005; 11: 317-320.
15. Wang CB, Wang CJ, Chou HH et al. Fertility-preserving treatment in young patients with endometrial adenocarcinoma. Cancer 2002; 94: 2192-2198.
16. Montz FJ, Bristow RE, Bovicelli A et al. Intrauterine progesterone treatment of early endometrial cancer. Am J Obstet Gynecol 2002; 186: 651-657.
17. Ørbo A, Arnes M, Hancke C et al. Treatment results of endometrial hyperplasia after prospective D-score classification A follow-up study comparing effect of LNG-IUD and oral progestins versus observation only. Gynecol Oncol 2008; 111: 68-73.
18. Wildemeersch D, Janssens D, Pylyser K et al. Management of patients with non-atypical and atypical endometrial hyperplasia with a levonorgestrelreleasing intrauterine system: long-term follow-up. Maturitas 2007; 57: 210-213.
19. Varma R, Soneja H, Bhatia K et al. The effectiveness of a levonorgestrelreleasing intrauterine system (LNG-IUS) in the treatment of endometrial hyperplasia-a long-term follow-up study. Eur J Obstet Gynecol Reprod Biol 2008; 139: 169-175.
20. Zaino R, Kauderer J, Trimble C et al. Reproducibility of the diagnosis of atypical endometrial hyperplasia. Cancer 2006; 106: 804-811.
21. Creasman WT, Odicino F, Pecorelli S et al. Carcinoma of the corpus uteri: FIGO annual report on the result of treatment in gynaecological cancer. J Epidemiol Biostat 2001; 6: 45-86.
22. Zerbe MJ, Bristow R, Grumbine FC et al. Inability of preoperative computed tomography scans to accuracy predict the extent of myometrial invasion and extracorporal spread in endometrial cancer. Gynecol Oncol 2000; 78: 67-70.
23. Horowitz NS, Dehdashti F, Herzog TJ et al. Prospective evaluation of FDG-PET for detecting pelvic and para-aortic lymph node metastasis in uterine corpus cancer. Gynecol Oncol 2004; 95: 546-551.
24. Takeshima N, Hirai Y, Yano K et al. Ovarian metastasis in endometrial carcinoma. Gynecol Oncol 1998; 70: 183-187.
25. Morice P, Fourchotte V, Sideris L et al. A need for laparoscopic evaluation of patients with endometrial carcinoma selected for conservative treatment. Gynecol Oncol 2005; 96: 245-248.
26. Frumovitz M, Gerhenson D. Fertility-sapring therapy for young women with endometrial cancer. Expert Rev Anticancer Ther 2006; 6: 27-32.
27. Chyong-Huey L, Huei-Jean H. The role of hormones for the treatment of endometrial hyperplasia and endometrial cancer. Curr Opin Obstet Gynecol 2006; 18: 29-34.
28. Ota T, Yoshida M, Kimura M et al. Clinicopathologic study of uterine endometrial cancinoma in young women aged 40 years and younger. Int J Gynecol Cancer 2005; 15: 657-662.
29. Dhar K, NeedhiRajan T, Koslowski M et al. Is levonorgestrel intrauterine system effective for treatment of early endometrial cancer? Report of four cases and review of the literature. Gynecol Oncol 2005; 97: 924-927.
30. Leslie KK, Stein MP, Kumar NS et al. Progesterone receptor isoform identification and subcellular localization in endometrial cancer. Gynecol Oncol 2005; 96: 32-41.
31. Wang SJ, Sakamoto T, Yasuda Si S et al. The relationship between telomere length and telomerase activity in gynecologic cancers. Gynecol Oncol 2002; 84: 81-84.